Drugs / Mtb72F/AS02A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00146744 | Jul 2005 → May 2006 | tuberculosis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mtb72F/AS02A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00146744 ↗ |
| Modality | Vaccine | “Mtb72F/AS02A is a candidate TB vaccine under development” NCT00146744 ↗ |
| Route | Intramuscular | “Mtb72F/AS02A Administered Intramuscularly at 0, 1, 2 Months” NCT00146744 ↗ |